The treatment of tardive dyskinesia-a systematic review and meta-analysis

Schizophrenia Research

Volumn 39, Issue 1, 1999, Pages 1-16

  Soares, K V S ^a   McGrath, J J ^b  

^a GERTNER INSTITUTE FOR EPIDEMIOLOGY AND HEALTH POLICY RESEARCH   (Israel)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Interventions; Meta analysis; Tardive dyskinesia

Indexed keywords

ALPHA TOCOPHEROL; ALPRAZOLAM; BACLOFEN; BROMOCRIPTINE; CERULETIDE; CLONIDINE; DEANOL; DIAZEPAM; DIHYDROERGOTOXINE MESILATE; ESTROGEN; GAMMA LINOLENIC ACID; INSULIN; LEVODOPA; LITHIUM; METHYLDOPA; NEUROLEPTIC AGENT; OXYPERTINE; PHOSPHATIDYLCHOLINE; PLACEBO; PROGABIDE; RESERPINE; SELEGILINE; TETRAHYDROISOXAZOLOPYRIDINOL; TIAPRIDE; VALPROIC ACID;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DATA ANALYSIS; DRUG EFFICACY; DRUG SAFETY; HUMAN; MENTAL DISEASE; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCHIZOPHRENIA; TARDIVE DYSKINESIA; TREATMENT OUTCOME; TYPES OF STUDY;

EID: 0033394021     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(99)00021-3     Document Type: Article

References (86)

1. Adler L.A., Peselow E., Rotrosen J., Duncan E., Lee M., Rosenthal M., Angrist B. Vitamin E treatment of tardive dyskinesia. Am. J. Psychiatry. 150:1993;1405-1407.
2. Adler L.A., Edson R., Lavori P., Peselow E., Duncan E., Rosenthal M., Rotrosen J. Long-term treatment effects of Vitamin E for tardive dyskinesia. Biol. Psychiatry. 43:1998;868-872.
3. Akhtar S., Jajor T.R., Kumar S. Vitamin E in the treatment of tardive dyskinesia. J. Postgrad. Med. 39:1993;124-126.
4. Altman D.G. Practical Statistics for Medical Research. 1991;Chapman & Hall, London.
5. Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association. 1992;American Psychiatric Press, Washington, DC.
6. Ananth J., Djenderedjian A., Beshay M., Kamal M., Kodjian A., Barriga C. Baclofen in the treatment of tardive dyskinesia. Curr. Ther. Res. Clin. E. 42:1987;111-114.
7. Armitage P. Br. J. Clin. Pharmacol. 32:1991;1-2.
8. Armstrong C.J. World Databases in Medicine. 1993;Bowker-Saur, London.
9. Barnes T.R.E., Edwards J.G. The side-effects of antipsychotic drugs. I. CNS and neuromuscular effects. Barnes T.R.E. Antipsychotic Drugs and their Side-effects. 1993;Harcourt Brace & Company, London.
10. Begg C., Cho M., Eastwood S., Horton R., Moher D., Olkin I., Pitkin R., Rennie D., Schulz K.F., Simel D., Stroup D.F. Improving the quality of reporting of randomized controlled trials: the CONSORT statement. J. Am. Med. Assoc. 276:1996;637-639.
11. Browne J., Silver H., Martin R., Hart R., Mergener M., Willians P. The use of clonidine in the treatment of neuroleptic-induced tardive dyskinesia. J. Clin. Psychopharmacol. 6:1986;88-92.
12. Burner M., Giroux C., Lheritier C., Garreau M., Morselli P.L. Preliminary observations on the therapeutic action of progabide in tardive dyskinesia. Brain Dysfunc. 2:1989;289-296.
13. Buruma O.J.S., Roos R.A.C., Bruyn G.W., Kemp B., van der Velde E.A. Tiapride in the treatment of tardive dyskinesia. Acta Neurol. Scand. 65:1982;38-44.
14. Casey D., Gerlach J. Tardive dyskinesia: what is the long-term outcome? Casey D., Gardos G. Tardive Dyskinesia and Neuroleptics: from Dogma to Reason. 1986;76-97 American Psychiatric Press, Washington, DC.
15. Chalmers I., Dickersin K., Chalmers T.C. Getting to grips with Archie Cochrane's agenda. Br. Med. J. 305:1992;786.
16. Chalmers I., Altman D.G. Systematic Reviews. 1995;BMJ Publishing Group, London.
17. Chalmers I., Sackett D., Silagy C. The Cochrane Collaboration. Maynard A., Chalmers I. Non-Random Reflections on Health Services Research. 1st Ed. 1997;BMJ Publications, London.
18. Chatellier G., Zapletal E., Lemaitre D., Menard J., Degoulet P. The number needed to treat: a clinically useful nomogram in its proper context. Br. Med. J. 312:1996;426-429.
19. Chouinard G. Effects of risperidone in tardive dyskinesia: An analysis of the Canadian multicenter risperidone study. J. Clin. Psychopharmacol. 15:(Suppl. 1):1995;36-44.
20. The Cochrane Library (database on disk and CD ROM). 1998;Update Software, Oxford. Issue 1.
21. Cookson I.B. The effects of a 50% reduction of cis(z)-flupenthixol decanoate in chronic schizophrenic patients maintained on a high dose regime. Int. Clin. Psychopharmacol. 2:1987;141-149.
22. Csernansky J.G., Tacke U., Rusen D., Hollister L.E. The effect of benzodiazepines on tardive dyskinesia symptoms. J. Clin. Psychopharmacol. 8:1988;154.
23. Dabiri L.M., Pasta D., Darby J.K., Mosbacher D. Effectiveness of vitamin E for treatment of long-term tardive dyskinesia. Am. J. Psychiatry. 151:(Suppl. 6):1994;925-926.
24. Davey-Smith G., Egger M. Meta-analysis: Unresolved issues and future developments. Br. Med. J. 316:1998;221-225.
25. de Montigny C., Chouinard G., Annable L. Ineffectiveness of deanol in tardive dyskinesia: A placebo controlled study. Psychopharmacology. 65:1979;219-223.
26. Egan M.F., Hyde T.M., Albers G.W., Elkashef A., Alexander R.C., Reeve A., Blum A., Saenz R.E., Wyatt R.J. Treatment of tardive dyskinesia with vitamin E. Am. J. Psychiatry. 149:1992;773-777.
27. Egan M.F., Apud J., Wyatt R.J. Treatment of tardive dyskinesia. Schizophr. Bull. 23:1997;583-609.
28. Egger M., Davey-Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. Br. Med. J. 315:1997;629-634.
29. Egger M., Schneider M., Davey-Smith G. Meta-analysis: Spurious precision? Meta-analysis of observational studies. Br. Med. J. 316:1998;140-144.
30. Egger M., Davey-Smith G. Meta-analysis: Bias in location and selection of studies. Br. Med. J. 316:1998;61-68.
31. Elkashef A.M., Ruskin P.E., Bacher N., Barrett D. Vitamin E in the treatment of tardive dyskinesia. Am. J. Psychiatry. 147:1990;505-506.
32. Fisk G.G., York S.M. The effect of sodium valproate on tardive dyskinesia - Revisited. Br. J. Psychiatry. 150:1987;542-546.
33. Fleiss J.L. The statistical basis of meta-analysis. Stat. Meth. Med. Res. 2:1993;121-145.
34. Frances A., Docherty J.P., Khan D.A. The Expert Consensus Guidelines Series: treatment of schizophrenia. J Clin Psychiatry. 57:(Suppl. 12B):1996;1-57.
35. Freeman H.L., Soni S.D., Carpenter L. A controlled trial of oxypertine in tardive dyskinesia. Int. Pharmacopsychiatr. 15:1980;281-291.
36. Gardos G., Granacher R.P., Cole J.O., Sniffin C. The effects of papaverine in tardive dyskinesia. Prog. Neuro-Psychopharmacol. 3:1979;543-550.
37. George J., Pridmore S., Aldous D. Double blind controlled trial of deanol in tardive dyskinesia. Aust. NZ J. Psychiatry. 15:1981;68-71.
38. Gerlach J., Rye T., Kristjansen P. Effect of baclofen on tardive dyskinesia. Psychopharmacology. 56:1978;145-151.
39. Gilbert P.L., Harris J., McAdams L.A., Jeste D.V. Neuroleptic withdrawal in schizophrenia patients: a review of the literature. Arch. Gen. Psychiatry. 52:1995;173-188.
40. Glazer W.M., Naftolin F., Morgenstern H., Barnea E.R., MacLusky N.J., Brenner L.M. Estrogen replacement and tardive dyskinesia. Psychoneuroendocrinology. 10:1985;345-350.
41. Goff D.C., Renshaw P.F., Saridsegal O., Dreyfuss D.A., Amico E.T., Ciraulo D.A. A placebo-controlled trial of selegiline (L-deprenyl) in the treatment of tardive dyskinesia. Biol. Psychiatry. 3:1993;700-706.
42. Guyatt G.H., Sackett D.L., Sinclair J.C., Hayward R., Cook D.J., Cook R.J. User's guide to the medical literature IX: a method for grading health care recommendations. J. Am. Med. Assoc. 274:1995;1800-1804.
43. Hajioff J., Wallace M. Effect of co-dergocrine mesylate on tardive dyskinesia. A preliminary report. Psychopharmacology. 79:1983;1-3.
44. Huang C.C., Wang R.I.H., Hasegawa A., Alverno L. Evaluation of reserpine and alpha-methyldopa in the treatment of tardive dyskinesia. Psychopharmacol. Bull. 16:1980;41-43.
45. Jackson I.V. Cholinergic enhancement in tardive dyskinesia. Curr. Ther. Res. Clin. E. 24:1978;725-733.
46. Jackson I.V., Nuttall E.A., Ibe I.O., Perezcruet J. Treatment of tardive dyskinesia with lecithin. Am. J. Psychiatry. 136:1979;1458-1460.
47. Jadad A.R., Moore A., Carrol D., Jenkinson C., Reynolds D.J.M., Gavaghan D.J., Mcquay H.J. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin. Trials. 17:1996;1-12.
48. Jeste D.V., Wyatt R.J. Therapeutic strategies against tardive dyskinesia: two decades of experience. Arch. Gen. Psychiatry. 39:1982;803-816.
49. Jeste D.V., Lohr J.B., Clark K., Wyatt R.J. Pharmacological treatments of tardive dyskinesia in the 1980s. J. Clin. Psychopharmacol. 8:(4S):1988;38S-48S.
50. Kane J.M., Rifkin A., Woerner M., Reardon G., Sarantakos S., Schiebel D., Ramos-Lorenzi J. Low-dose neuroleptic treatment of outpatient schizophrenics I. Preliminary results for relapse rates. Arch. Gen. Psychiatry. 40:1983;893-896.
51. Karniol I.G., Giampietro A.C., Moura D.S., Vilela W.A., Oliveira M.A., Zuardi A.W. Estudo duplo-cego sobre a acao de L-dopa em pacientes psicoticos com discinesia tardia. Acta Psiquiat. Psicolog. Am. Lat. 29:1983;261-266.
52. Kazamatsuri H., Chien C., Cole J.O. Therapeutic approaches to tardive dyskinesia: A review of the literature. Arch. Gen. Psychiatry. 27:1972;491-499.
53. Kennedy E., Song F., Hunter R., Gilbody S. Risperidone versus "conventional" antipsychotic medication for schizophrenia. Adams C.E., Duggan L., Wahlbeck K., White P. Schizophrenia Module of The Cochrane Database of Systematic Reviews. 1998;Update Software, Oxford. Available in The Cochrane Library (database on disk and CD ROM). The Cochrane Collaboration; Issue 1.
54. Khan K.S., Daya S., Jadad A.R. The importance of quality of primary studies in producing unbiased systematic reviews. Arch. Intern. Med. 156:1996;661-666.
55. Kocher R., Hobi V., Linder M., Studer K. Zur therapie mit dimethylaminoathanol (deanol) bei neuroleptikainduzierten spatdyskinesien. Schweiz Arch. Neurol. Neuroch. Psychiat. 126:1980;103-109.
56. Kojima T., Yamauchi T., Miyasaka M., Koshino Y., Nakane Y., Takahashi R., Shimazono Y., Yagi G. Treatment of tardive dyskinesia with ceruletide: A double-blind, placebo-controlled study. Psychiatry Res. 43:1992;129-136.
57. Kraemer H.C., Pruyn J.P. The evaluation of different approaches to randomized clinical trials. Arch. Gen. Psychiatry. 47:1990;1163-1169.
58. Lam L.C.W., Chiu H.F.K., Hung S.F. Vitamin E in the treatment of tardive dyskinesia: A replication study. J. Nerv. Ment. Dis. 182:1994;113-114.
59. Leblhuber F., Reisecker F., Bengesser G. Tiaprid in der Behandlung irreversibler tardiver Dyskinesien - erste Erfahrungen. Z. Gerontol. 20:1987;49-51.
60. Lieberman J.A., Alvir J., Mukherjee S., Kane J.M. Treatment of tardive dyskinesia with bromocriptine. A test of the receptor modification strategy. Arch. Gen. Psychiatry. 46:1989;908-913.
61. Linnoila M., Viukari M., Kietala O. Effect of sodium valproate on tardive dyskinesia. Br. J. Psychiatry. 129:1976;114-119.
62. Lohr J.B., Lavori P. Whither Vitamin E and tardive dyskinesia? Biol. Psychiatry. 43:1998;861-862.
63. Ludatscher J.I. Stable remission of tardive dyskinesia by L-dopa. J. Clin. Psychopharmacol. 9:1989;39-41.
64. Mackay A.V.P., Sheppard G.P., Saha B.K., Motley B., Johnson L., Marsden C.D. Failure of lithium treatment in established tardive dyskinesia. Psychol. Med. 10:1980;583-587.
65. Mackay A.V.P., Sheppard G.P. Pharmacotherapeutic trials in tardive dyskinesia. Kerr A., Snaith P. Contemporary Issues in Schizophrenia. 1982;Gaskell, London.
66. McGrath J.J., Davies G., Soares K. Writing to authors of systematic reviews elicited further data in 17% of cases. Br. Med. J. 316:1998;631.
67. Matsunaga T., Ohyama S., Takehara S., Kabashima K., Moriyama S., Tsuzuki J., Ikeda H., Suematsu M., Akizuki K., Fujimoto K. The effect of ceruletide on tardive dyskinesia: A double-blind placebo-controlled study. Progr. Neuro-Psychopharmacol. 12:1988;533-539.
68. Mouret J., Khomais M., Lemoine P., Sebert P. Low doses of insulin as a treatment of tardive dyskinesia: Conjuncture or conjecture? Eur. Neurol. 31:1991;199-203.
69. Mulrow C.D., Oxman A.D. Cochrane Collaboration Handbook. 1996;Update Software, Oxford. CD ROM - updated quartely. Available in the Cochrane Library.
70. Nair N.P., Yassa R., Ruiznavarro J., Schwartz G. Baclofen in the treatment of tardive dyskinesia. Am. J. Psychiatry. 135:1978;1562-1563.
71. Rust M. Tiapride treatment of tardive dyskinesia due to long-term neuroleptic treatment. Sem. Hop. Paris. 60:1984;2195-2196.
72. Sackett D.L., Richardson W.S., Rosenberg W., Haynes R.B. Evidence-Based Medicine: How to Practice and Teach EBM. 1997;Churchill Livingstone, London.
73. Sackett D.L., Wennberg J.E. Choosing the best research design for each question: it's time to stop squabbling over the "best" methods. Br. Med. J. 315:1997;1636-1637.
74. Schmidt M., Meister P., Baumann P. Treatment of tardive dyskinesias with vitamin E. Eur. Psychiatry. 6:1991;201-207.
75. Schooler N.R., Keith S.J. The clinical research base for the treatment of schizophrenia. Psychopharmacol. Bull. 29:1993;431-446.
76. Schulz K.F., Chalmers I., Hayes R.J., Altman D.G. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. J. Am. Med. Assoc. 273:1995;408-412.
77. Simpson G.M., Yadalam K.G., Stephanos M.J. Double-blind carbidopa/levodopa and placebo study in tardive dyskinesia. J. Clin. Psychopharmacol. 8:(Suppl. 4):1988;49-51.
78. Soni S.D., Freeman H.L., Hussein E.M. Oxypertine in tardive dyskinesia: An 8-week controlled study. Br. J. Psychiatry. 144:1984;48-52.
79. Soni S.D., Freeman H.L., Bamrah J.S., Sampath G. Oxypertine in tardive dyskinesia: A long-term controlled study. Acta Psychiatr. Scand. 74:1986;446-450.
80. Stewart R.M., Rollins J., Beckham B., Roffman M. Baclofen in tardive dyskinesia patients maintained on neuroleptics. Clin. Neuropharmacol. 5:1982;365-373.
81. Tarsy D., Bralower M. Deanol acetamidobenzoate treatment in choreiform movement disorders. Arch. Neurol. 34:1977;756-758.
82. Thaker G.K., Tamminga C.A., Alphs L.D., Lafferman J., Ferraro T.N., Hare T.A. Brain gamma-aminobutyric acid abnormality in tardive dyskinesia: Reduction in cerebrospinal fluid GABA levels and therapeutic response to GABA agonist treatment. Arch. Gen. Psychiatry. 44:1987;522-529.
83. Tollefson G.D., Beasley C.M., Tran P.V., Street J.S., Krueger J.A., Tamura R.N., Graffeo K.A., Thieme M.E. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial. Am. J. Psychiatry. 154:1997;457-465.
84. Weber S.S., Dufresne R.L., Becker R.E., Mastrati P. Diazepam in tardive dyskinesia. Drug Intel. Clin. Pharmacol. 17:1983;523-527.
85. Wolkin A., Jordan B., Peselow E., Rubinstein M., Rotrosen J. Essential fatty acid supplementation in tardive dyskinesia. Am. J. Psychiatry. 143:1986;912-914.
86. Scientific Group on Treatment of Psychiatric Disorders: Evaluation of Methods for the Treatment of Mental Disorders. 1991;World Health Organization, Geneva.